Cabozantinib for kidney cancer in dialysis patients
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests the drug cabozantinib in people with kidney cancer who are also on dialysis. It aims to see if the drug is safe and works for this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or spread kidney cancer with clear-cell or papillary features.
- You have had at least one previous treatment for your kidney cancer.
- You have been on haemodialysis for more than 3 months without major complications.
- You have recovered from side effects of prior treatments (or side effects are stable and not serious).
- You are 18 years or older and are generally active (Karnofsky score 70% or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether tracking your symptoms with a digital app can help manage side effects while you receive two medications (cabozantinib and nivolumab) for advanced clear-cell kidney cancer that hasn't been treated before.
This trial is testing a combination of two drugs, cabozantinib and nivolumab, in people aged 70 or older who have advanced kidney cancer that hasn't been treated yet. The goal is to see if this combination works well and is safe for older patients.
This Phase 2 study tests a “next-step” cabozantinib strategy for advanced kidney cancer (RCC) after your cancer previously responded to cabozantinib and then progressed. It aims to see if re-using cabozantinib in a planned sequence can control the cancer again with manageable side effects.
This study tests whether adding a drug called cabozantinib to standard nivolumab treatment helps fight kidney cancer that has spread to bone. It aims to understand how the bone environment changes during treatment.
This trial tests a new drug (casdatifan) combined with cabozantinib for advanced clear cell kidney cancer, comparing it to cabozantinib alone. It's for people who haven't taken these specific medicines before and are still in fairly good health.
This study looks at whether closer monitoring of cabozantinib levels in the blood can help doctors manage side effects better. It's for people with advanced kidney cancer who are already planning to take cabozantinib.
Hear when a new Cancer of Kidney trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.